Video

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Medstar Health, discusses varying treatment options for patients with metastatic colorectal cancer (mCRC).

One of the more common types of frontline treatment for patients with mCRC is backbone chemotherapy of 5-fluorouracil (5-FU) or capecitabine (Xeloda). Secondary chemotherapy agents that would be added to the backbone include oxaliplatin or irinotecan. Additionally, physicians can add biologics that target the VEGF pathway, such as bevacizumab (Avastin) or cetuximab (Erbitux), which only work for patients who have KRAS, NRAS, or BRAF wild-type mCRC. Patients with left-sided tumors also typically benefit most from the addition of either bevacizumab or cetuximab.

Lesser-common subsets of patients with mCRC, such as microsatellite instability—high disease, can be treated with PD-1 inhibitors. Additionally, entrectinib (Rozlytrek) and larotrectinib (Vitrakvi) are 2 agents approved for patients NTRK fusion–positive tumors, Weinberg concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity